GlassScriptPhysician profile
Haris Turalic
NPI 1992987770
$13,577.80
in general payments reported to CMS, 2019-2025
34 companies · $1,863 in 2025
The $1,863 reported for 2025 was more than what 82% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $975 · 2020: $1,638 · 2021: $2,417 · 2022: $1,836 · 2023: $2,120 · 2024: $2,729 · 2025: $1,863.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,693 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,692.53 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,441.22 | 2019-2024 | Xarelto |
| Cvrx, INC. | $1,296.11 | 2020-2025 | Barostim Neo System |
| Amarin Pharma, INC. | $1,166.03 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $962.54 | 2019-2025 | Farxiga, Brilinta |
| Amgen INC. | $756.03 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $751.96 | 2021-2025 | Verquvo, Capvaxive |
| Kestra Medical Technology Services, INC. | $721.25 | 2023-2025 | Assure Wcd |
| Bayer Healthcare Pharmaceuticals INC. | $718.69 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $693.07 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $602.65 | 2019-2025 | |
| Scpharmaceuticals INC. | $552.80 | 2024-2025 | |
| Pfizer INC. | $460.94 | 2019-2025 | |
| Lexicon Pharmaceuticals, INC. | $432.91 | 2023-2024 | Inpefa |
| E.R. Squibb & Sons, L.L.C. | $432.04 | 2019-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $421.77 | 2019-2025 | Lifevest |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $347.76 | 2020-2024 | (5091) Amb Mon & Diag Und, (Cm9) Amb Mon & Diag Und |
| Alnylam Pharmaceuticals INC. | $278.17 | 2022-2024 | Onpattro |
| Boston Scientific Corporation | $262.48 | 2020-2024 | Watchman Flx |
| Abbott Laboratories | $255.96 | 2023-2025 | Mitraclip |
| Sanofi-Aventis U.S. LLC | $240.74 | 2019-2023 | |
| Astellas Pharma US INC | $147.49 | 2019-2022 | |
| Medtronic, INC. | $128.55 | 2021 | |
| Novo Nordisk INC | $105.30 | 2021-2025 | Ozempic |
| Actelion Pharmaceuticals US, INC. | $73.03 | 2020 | |
| Ge Healthcare | $54.60 | 2020 | |
| Esperion Therapeutics, INC. | $49.33 | 2024-2025 | Nexletol |
| Irhythm Technologies, INC. | $42.44 | 2019-2021 | |
| Abiomed | $37.90 | 2024 | Impella |
| Corvista Health, INC. | $34.13 | 2025 | Corvista System |
| Kiniksa Pharmaceuticals International, Plc | $31.69 | 2024 | Arcalyst |
| Braemar Manufacturing, LLC | $24.85 | 2019 | |
| Medtronic Vascular, INC. | $19.33 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $17.05 | 2019 | |
| Edwards Lifesciences Corporation | $16.99 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haris Turalic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.